methylphenidate and Cognitive Decline studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Research Excerpts

Excerpt	Relevance	Reference
" Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)."	5.22	Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022)
"This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients."	4.98	The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review. ( Andrew, BN; Guan, NC; Jaafar, NRN, 2018)
"Methylphenidate was well tolerated while galantamine produced gastrointestinal side effects in a considerable number of patients."	2.94	Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. ( Barkhof, F; Groeneveld, GJ; Klaassen, ES; Leeuwis, AE; Leijenaar, JF; Prins, ND; Scheltens, P; van der Flier, WM; van Gerven, JMA; Weinstein, HC, 2020)
"Ten participants with mild cognitive impairment or mild-stage dementia due to AD/ADRDs will undergo a 4-week lead-in period followed by three, month-long treatment blocks (2 weeks of treatment with methylphenidate, 2 weeks placebo in random order)."	2.94	A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment. ( Arnold, SE; Azami, H; Betensky, RA; Bolling, AM; Carlyle, BC; Cook, CL; DesRuisseaux, LA; Gerber, JA; Gupta, AS; McManus, AJ; Williams, VJ, 2020)
"Methylphenidate was associated with significant improvements in processing speed, sustained attention, and both lab-based and everyday executive functioning."	2.90	Influence of Methylphenidate on Long-Term Neuropsychological and Everyday Executive Functioning After Traumatic Brain Injury in Children with Secondary Attention Problems. ( Horn, PS; Kurowski, BG; LeBlond, E; Riemersma, JJ; Smith-Paine, J; Wade, SL, 2019)
" Outcomes were the improvement of apathy scales score (primary), mini-mental state examination (MMSE) score, activities of daily living scale score, Zarit burden interview score, all-cause discontinuation, discontinuation due to adverse events, and incidence of at least 1 adverse event."	2.66	Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis. ( Iwata, N; Kishi, T; Sakuma, K, 2020)
"Cognitive dysfunction is a challenging adverse effect of chemotherapy and radiotherapy that has limited treatment options."	2.61	Pharmacologic management of cognitive impairment induced by cancer therapy. ( Dietrich, J; Karschnia, P; Parsons, MW, 2019)
"Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck."	2.50	Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. ( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014)
"Methylphenidate (MPH) is a psychostimulant widely misused to increase wakefulness by drivers and students."	1.62	Stimulants cocktail: Methylphenidate plus caffeine impairs memory and cognition and alters mitochondrial and oxidative status. ( Barcellos, LJG; de Alcantara Barcellos, HH; Fortuna, M; Freddo, N; Koakoski, G; Maffi, VC; Mozzato, MT; Pompermaier, A; Rossato-Grando, LG; Soares, SM; Varela, ACC, 2021)

Research

Studies (22)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Cognition as Measured by Daily, Home-based Brain Games (Lumosity, Lumos Labs, Inc.)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	15 (68.18)	24.3611
2020's	7 (31.82)	2.80

Authors	Studies
Kirkman, MA	3
Day, J	3
Gehring, K	3
Zienius, K	3
Grosshans, D	3
Taphoorn, M	3
Li, J	3
Brown, PD	3
Motaghinejad, M	1
Motevalian, M	1
Ulloa, L	1
Kaviani, N	1
Hamurtekin, E	1
Leijenaar, JF	1
Groeneveld, GJ	1
Klaassen, ES	1
Leeuwis, AE	1
Scheltens, P	1
Weinstein, HC	1
van Gerven, JMA	1
Barkhof, F	1
van der Flier, WM	1
Prins, ND	1
Kishi, T	1
Sakuma, K	1
Iwata, N	1
Freddo, N	1
Soares, SM	1
Fortuna, M	1
Pompermaier, A	1
Varela, ACC	1
Maffi, VC	1
Mozzato, MT	1
de Alcantara Barcellos, HH	1
Koakoski, G	1
Barcellos, LJG	1
Rossato-Grando, LG	1
DesRuisseaux, LA	1
Williams, VJ	1
McManus, AJ	1
Gupta, AS	1
Carlyle, BC	1
Azami, H	1
Gerber, JA	1
Bolling, AM	1
Cook, CL	1
Betensky, RA	1
Arnold, SE	1
Zhand, N	1
Harvey, P	1
Osborne, R	1
Hatko, A	1
Stuyt, M	1
Labelle, A	1
Andrew, BN	1
Guan, NC	1
Jaafar, NRN	1
McLaurin, KA	1
Li, H	1
Booze, RM	1
Fairchild, AJ	1
Mactutus, CF	1
Quinn, DK	1
Mayer, AR	1
Master, CL	1
Fann, JR	1
Johansson, B	1
Wentzel, AP	1
Andréll, P	1
Rönnbäck, L	1
Mannheimer, C	1
Ramon-Duaso, C	1
Gener, T	1
Consegal, M	1
Fernández-Avilés, C	1
Gallego, JJ	1
Castarlenas, L	1
Swanson, MS	1
de la Torre, R	1
Maldonado, R	1
Puig, MV	1
Robledo, P	1
Boris, JR	1
Bernadzikowski, T	1
Karschnia, P	1
Parsons, MW	1
Dietrich, J	1
LeBlond, E	1
Smith-Paine, J	1
Riemersma, JJ	1
Horn, PS	1
Wade, SL	1
Kurowski, BG	1
Jenkins, PO	1
De Simoni, S	1
Bourke, NJ	1
Fleminger, J	1
Scott, G	1
Towey, DJ	1
Svensson, W	1
Khan, S	1
Patel, MC	1
Greenwood, R	1
Friedland, D	1
Hampshire, A	1
Cole, JH	1
Sharp, DJ	1
Miladi, N	1
Dossa, R	1
Dogba, MJ	1
Cléophat-Jolicoeur, MIF	1
Gagnon, B	1
Fyfe, I	1
Butzbach, M	1
Fuermaier, ABM	1
Aschenbrenner, S	1
Weisbrod, M	1
Tucha, L	1
Tucha, O	1
Castellino, SM	1
Ullrich, NJ	1
Whelen, MJ	1
Lange, BJ	1
Bilder, RM	1
Loo, SK	1
McGough, JJ	1
Whelan, F	1
Hellemann, G	1
Sugar, C	1
Del'Homme, M	1
Sturm, A	1
Cowen, J	1
Hanada, G	1
McCracken, JT	1
Fosco, WD	1
White, CN	1
Hawk, LW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Symptomatic Treatment of Vascular Cognitive Impairment[NCT02098824]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia[NCT03811847]	Phase 4	11 participants (Actual)	Interventional	2019-11-01	Completed
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719]		200 participants (Anticipated)	Interventional	2020-11-08	Recruiting
An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years[NCT00429273]	Phase 4	212 participants (Actual)	Interventional	2007-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

This study is investigating the effects of methylphenidate to see if it will help improve cognition in adults with Alzheimer's Disease using daily Lumosity brain games. The range of possible Lumosity scores varies, but higher scores indicate better game performance. LPI (Lumosity Performance Index) is a standardized performance metric that shows how well you are performing on Lumosity games and lets you compare performance across games and Cognitive Areas. Cognitive LPI is calculated using a weighted average of the Game LPIs from all Cognitive Areas. LPI: The low score is 0, the high score is 2000. Average is 1000. (NCT03811847)
Timeframe: 4 months

Cognition as Measured by the Repeatable Battery for the Assessment Neuropsychological Status-Update (RBANS)

Intervention	scores on a scale (Mean)
Study Participants on MPH Blocks	465.8
Study Participants on Placebo	451.6

This study is investigating the effects of methylphenidate to see if it will help improve cognition in adults with Alzheimer's Disease. RBANS scores range from 40 to 160 with higher scores indicating higher cognitive functioning. (NCT03811847)
Timeframe: 4 months

Feasibility of a Virtual Multicrossover Randomized Control Trial Design as Measured my Completion Rates and Medication Compliance.

Intervention	scores on scale (Mean)
Study Participants on MPH Treatment	68.8
Study Participants on PBO Block	70.7

To assess feasibility of this study design, completion rates of all study tasks and medication dosing will be evaluated. Benchmark goals for feasibility measures are set as follows: retain >80% of participants enrolled, observe >80% medication adherence, and >80% outcome assessment completion rates. (NCT03811847)
Timeframe: 4 months

ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)

Intervention	Participants (Count of Participants)
	Participant retention	Medication Compliance	Assessment completion
All Study Participants	7	7	7

"The primary clinical efficacy variable for treatment was the ADHD-RS-IV (Attention-Deficit/Hyperactivity Disorder Rating Scale) Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ).~The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3). Min 0; max 3.~Scores are obtained by summing each item; The higher the score, the worse the outcome.~Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27" (NCT00429273)
Timeframe: Measured at baseline Week 4 and Week 8

Intervention	units on a scale (Least Squares Mean)
	Total ADHD-RS Score	Inattentive Subscale	Hyperactive Impulsive Subscale
Estimated Difference Between DMPH and Placebo	-7.99	-4.10	-4.0
Estimated Difference Between Guan and Placebo	-7.77	-4.14	-3.73
Estimated Difference Between Placebo and Combo	-10.66	-5.89	-5.10

Article	Year
Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. Alzheimer's research & therapy, 2020, 01-07, Volume: 12, Issue:1 Topics: Aged; Central Nervous System Stimulants; Cognitive Dysfunction; Cross-Over Studies; Dementia, Vascul	2020
A pilot protocol to assess the feasibility of a virtual multiple crossover, randomized controlled trial design using methylphenidate in mild cognitive impairment. Trials, 2020, Dec-11, Volume: 21, Issue:1 Topics: Cognitive Dysfunction; Feasibility Studies; Humans; Methylphenidate; Pilot Projects; Randomized Cont	2020
Influence of Methylphenidate on Long-Term Neuropsychological and Everyday Executive Functioning After Traumatic Brain Injury in Children with Secondary Attention Problems. Journal of the International Neuropsychological Society : JINS, 2019, Volume: 25, Issue:7 Topics: Adolescent; Attention; Brain Injuries, Traumatic; Central Nervous System Stimulants; Child; Cognitiv	2019
Stratifying drug treatment of cognitive impairments after traumatic brain injury using neuroimaging. Brain : a journal of neurology, 2019, 08-01, Volume: 142, Issue:8 Topics: Adult; Brain; Brain Injuries, Traumatic; Central Nervous System Stimulants; Cognitive Dysfunction; C	2019
Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, Volume: 55, Issue:8 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Cen	2016
Acute Stimulant Treatment and Reinforcement Increase the Speed of Information Accumulation in Children with ADHD. Journal of abnormal child psychology, 2017, Volume: 45, Issue:5 Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognitive D	2017

Article	Year
Minocycline protects against neuronal mitochondrial dysfunction and cognition impairment. Acta neurobiologiae experimentalis, 2023, Volume: 83, Issue:1 Topics: Animals; Antioxidants; Cognition; Cognitive Dysfunction; Hippocampus; Male; Methylphenidate; Minocyc	2023
Stimulants cocktail: Methylphenidate plus caffeine impairs memory and cognition and alters mitochondrial and oxidative status. Progress in neuro-psychopharmacology & biological psychiatry, 2021, 03-02, Volume: 106 Topics: Animals; Caffeine; Central Nervous System Stimulants; Cognition; Cognitive Dysfunction; Female; Male	2021
Retrospective review of use of adjunctive psychostimulants in patients with schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2021, Volume: 33, Issue:1 Topics: Adjuvants, Pharmaceutic; Attention; Attention Deficit Disorder with Hyperactivity; Canada; Central N	2021
Unraveling Individual Differences In The HIV-1 Transgenic Rat: Therapeutic Efficacy Of Methylphenidate. Scientific reports, 2018, 01-09, Volume: 8, Issue:1 Topics: Animals; Behavior, Animal; Biological Variation, Population; Central Nervous System Stimulants; Cogn	2018
Prolonged Postconcussive Symptoms. The American journal of psychiatry, 2018, 02-01, Volume: 175, Issue:2 Topics: Accidents, Traffic; Adaptation, Psychological; Anxiety Disorders; Attention; Axons; Brain Concussion	2018
Two-Year Methylphenidate Treatment of Mental Fatigue and Cognitive Function After a Traumatic Brain Injury: A Clinical Prospective Study. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:2 Topics: Adult; Brain Injuries, Traumatic; Central Nervous System Stimulants; Cognitive Dysfunction; Female;	2018
Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression. Cerebral cortex (New York, N.Y. : 1991), 2019, 07-05, Volume: 29, Issue:7 Topics: Affect; Animals; Brain; Central Nervous System Stimulants; Cognition; Cognitive Dysfunction; Depress	2019
Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome. Cardiology in the young, 2018, Volume: 28, Issue:12 Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Central Nervous System Stimulan	2018
Predicting treatment response in post-TBI cognitive impairment. Nature reviews. Neurology, 2019, Volume: 15, Issue:9 Topics: Brain Injuries, Traumatic; Cognitive Dysfunction; Dopamine Uptake Inhibitors; Humans; Methylphenidat	2019
Basic processes as foundations of cognitive impairment in adult ADHD. Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:10 Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive D	2019

methylphenidate and Cognitive Decline